Protocol Ledger

NCT05799378 · Phase III · RECRUITING

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Interventional Phase III clinical trial protocol NCT05799378 sponsored by NYU Langone Health in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-27 Enrollment: 330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05799378
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05799378
Protocol FieldVerified Registry Value
NCT IdentifierNCT05799378
Consolidated Lead SponsorNYU Langone Health
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment330 participants (ESTIMATED)
Registered Start Date2024-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for NYU Langone Health across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI